FCR/BR
Phase 2Small molecule
FCR/BR is one of 17 small molecule programs targeting Monotherapy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Monotherapy
#DrugCompanyPhaseTrials
1Reblozyl
Bristol-Myers SquibbApproved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Opdivo
Bristol-Myers SquibbPhase 2
Stivarga
BayerPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Lenvima
EisaiPhase 2
Venclexta
AbbViePhase 2
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 2
Trifluridine/tipiracil
AbbViePhase 2
RP1
RReplimune Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FCR/BR. EMBL-EBI & Wellcome Sanger Institute.
- [4]